DIAGNOSIS, PROGNOSIS AND SCREENING FOR MEDICAMENTS FOR TREATMENT OF MYELOPROLIFERATIVE DISORDERS USING RECEPTOR PROTEIN TYROSINE-PHOSPHATASE GAMMA (PTPRG) AS BIOMARKER